Neurocrine Biosciences (NASDAQ: NBIX) has initiated a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-1968, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA